# Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors

> **NCT04226066** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Tasly Tianjin Biopharmaceutical Co., Ltd.** · enrollment: 69 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumors

## Interventions

- **BIOLOGICAL:** T601
- **COMBINATION_PRODUCT:** T601+5-FC

## Key facts

- **NCT ID:** NCT04226066
- **Lead sponsor:** Tasly Tianjin Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-20
- **Primary completion:** 2021-05-31
- **Final completion:** 2022-05-31
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2020-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04226066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04226066, "Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04226066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*